Following his company's $38-million acquisition last week of Gentra Systems, Qiagen CEO Peer Schatz suggested that the company was likely to stick with its strategy of acquiring smaller companies that generate near-term value.
Already have a GenomeWeb or 360Dx account?Login Now.
An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.
Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.
The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.
In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.